title: Community financing of local ivermectin distribution in Nigeria: potential payment and cost-recovery outlook.
abstract: The preferred payment mechanism in a community financing scheme for local ivermectin distribution was elicited from randomly selected household heads from three communities in Nigeria using interviewer-administered structured questionnaires. The majority of the respondents in the three communities were prepared to pay for local ivermectin distribution. Additionally, the average amounts the respondents were prepared to pay per person treated ($0.28, $0.30 and $0.38 in Nike, Achi and Toro, respectively) were all more than the $0.20 ceiling recommended by the partners of the African Programme on Onchocerciasis Control (APOC). Thus, the cost-recovery outlook is bright in these communities. However, the preferred payment modality varied. Fee-for-service was the predominant payment modality in the Achi and Nike communities, while the Toro community preferred pre-payment. This study demonstrates that many communities have different payment preferences for endemic disease control efforts. This knowledge will help in developing acceptable and sustainable schemes. The imposition of unacceptable payment mechanisms will lead to an unwillingness to pay.
authors.affiliation: Department of Pharmacology and Therapeutics College of Medicine, University of Nigeria, Enugu, Nigeria. o.onwujekwe@lshtm.ac.uk
authors.forename: O E
authors.initials: OE
authors.lastname: Onwujekwe
authors.forename: E N
authors.initials: EN
authors.lastname: Shu
authors.forename: P O
authors.initials: PO
authors.lastname: Okonkwo
mesh_terms: D000328:Adult; D001294:Attitude to Health; D003256:Community Participation; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019353:Endemic Diseases / Q000191:economics / Q000517:prevention & control* / Q000706:statistics & numerical data; D005260:Female; D005369:Filaricides / Q000191:economics* / Q000600:supply & distribution* / Q000627:therapeutic use; D005382:Financing, Personal / Q000379:methods*; D006801:Humans; D007559:Ivermectin / Q000191:economics* / Q000600:supply & distribution* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D009855:Onchocerciasis / Q000188:drug therapy* / Q000453:epidemiology; D015397:Program Evaluation; D011795:Surveys and Questionnaires
chemical_list: D005369:Filaricides; D007559:Ivermectin